EDGEWISE THERAPEUTICS INC (EWTX) Stock Price, Quote, News and Overview
NASDAQ:EWTX - Nasdaq - US28036F1057 - Common Stock - Currency: USD
EWTX Quote, Performance and Key Statistics
14.21
+0.19 (+1.36%)
The current stock price of EWTX is 14.21 USD. In the past month the price decreased by -4.25%. In the past year, price decreased by -16.95%.
EWTX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 51.87 | 676.59B | ||
| JNJ | JOHNSON & JOHNSON | 15.22 | 367.98B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 19.24 | 298.97B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.57 | 222.69B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 18.93 | 218.30B | ||
| MRK | MERCK & CO. INC. | 9.96 | 195.22B | ||
| PFE | PFIZER INC | 7.26 | 132.26B | ||
| SNY | SANOFI-ADR | 13.57 | 127.25B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.38 | 95.34B | ||
| GSK | GSK PLC-SPON ADR | 7.02 | 78.23B | ||
| ZTS | ZOETIS INC | 27.01 | 72.52B | ||
| HLN | HALEON PLC-ADR | 22.73 | 50.23B |
Related stock screener links
About EWTX
Company Profile
Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in Boulder, Colorado and currently employs 110 full-time employees. The company went IPO on 2021-03-26. The Company’s lead product candidate, sevasemten (EDG-5506), is an orally administered skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. Its EDG-7500 is a novel cardiac sarcomere modulator for the treatment of hypertrophic cardiomyopathy and other diseases of diastolic dysfunction, which is in Phase II clinical development. The firm is using its proprietary drug discovery platform to develop a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address a broad array of serious muscle disorders. Its platform utilizes custom-built high throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue.
Company Info
EDGEWISE THERAPEUTICS INC
1715 38Th St
Boulder COLORADO 80303 US
CEO: Kevin Koch
Employees: 97
Phone: 17202627002
EDGEWISE THERAPEUTICS INC / EWTX FAQ
What is the stock price of EDGEWISE THERAPEUTICS INC today?
The current stock price of EWTX is 14.21 USD. The price increased by 1.36% in the last trading session.
What is the ticker symbol for EDGEWISE THERAPEUTICS INC stock?
The exchange symbol of EDGEWISE THERAPEUTICS INC is EWTX and it is listed on the Nasdaq exchange.
On which exchange is EWTX stock listed?
EWTX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for EDGEWISE THERAPEUTICS INC stock?
16 analysts have analysed EWTX and the average price target is 41.59 USD. This implies a price increase of 192.71% is expected in the next year compared to the current price of 14.21. Check the EDGEWISE THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is EDGEWISE THERAPEUTICS INC worth?
EDGEWISE THERAPEUTICS INC (EWTX) has a market capitalization of 1.35B USD. This makes EWTX a Small Cap stock.
How many employees does EDGEWISE THERAPEUTICS INC have?
EDGEWISE THERAPEUTICS INC (EWTX) currently has 97 employees.
What are the support and resistance levels for EDGEWISE THERAPEUTICS INC (EWTX) stock?
EDGEWISE THERAPEUTICS INC (EWTX) has a support level at 14.2 and a resistance level at 14.6. Check the full technical report for a detailed analysis of EWTX support and resistance levels.
Should I buy EDGEWISE THERAPEUTICS INC (EWTX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of EWTX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of EWTX, evaluating the profitability, health, valuation and growth aspects
- EDGEWISE THERAPEUTICS INC (EWTX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- EDGEWISE THERAPEUTICS INC (EWTX) Sales and EPS estimates to see what analysts future expectations are.
- EDGEWISE THERAPEUTICS INC (EWTX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- EDGEWISE THERAPEUTICS INC (EWTX) Insider and Institutional Ownership to learn about the owners and their transactions.
- EDGEWISE THERAPEUTICS INC (EWTX) Stock Chart to make your own analysis
- EDGEWISE THERAPEUTICS INC (EWTX) Latest news and press-releases to stay up to date.
Does EDGEWISE THERAPEUTICS INC (EWTX) stock pay dividends?
EWTX does not pay a dividend.
When does EDGEWISE THERAPEUTICS INC (EWTX) report earnings?
EDGEWISE THERAPEUTICS INC (EWTX) will report earnings on 2025-08-06, before the market open.
What is the Price/Earnings (PE) ratio of EDGEWISE THERAPEUTICS INC (EWTX)?
EDGEWISE THERAPEUTICS INC (EWTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.55).
What is the Short Interest ratio of EDGEWISE THERAPEUTICS INC (EWTX) stock?
The outstanding short interest for EDGEWISE THERAPEUTICS INC (EWTX) is 18.37% of its float. Check the ownership tab for more information on the EWTX short interest.
EWTX Technical Analysis
EWTX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to EWTX. No worries on liquidiy or solvency for EWTX as it has an excellent financial health rating, but there are worries on the profitability.
EWTX Financial Highlights
Over the last trailing twelve months EWTX reported a non-GAAP Earnings per Share(EPS) of -1.55.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -32.15% | ||
| ROE | -34% | ||
| Debt/Equity | 0 |
EWTX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to EWTX. The Buy consensus is the average rating of analysts ratings from 16 analysts.